Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
12.57B
Market cap12.57B
Price-Earnings ratio
278.12
Price-Earnings ratio278.12
Dividend yield
—
Dividend yield—
Average volume
584.45K
Average volume584.45K
High today
$120.00
High today$120.00
Low today
$116.13
Low today$116.13
Open price
$116.27
Open price$116.27
Volume
513.72K
Volume513.72K
52 Week high
$126.38
52 Week high$126.38
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

The current Corcept Therapeutics(CORT) stock price is $116.28, with a market capitalization of 12.57B. The stock trades at a price-to-earnings (P/E) ratio of 278.12.

On 2026-10-22, Corcept Therapeutics(CORT) stock moved within a range of $116.13 to $120.00. With shares now at $116.28, the stock is trading +0.1% above its intraday low and -3.1% below the session's peak.

Trading activity shows a volume of 513.72K, compared to an average daily volume of 584.45K.

Over the past 52 weeks, Corcept Therapeutics(CORT) stock has traded between a high of $126.38 and a low of $28.66.

Over the past 52 weeks, Corcept Therapeutics(CORT) stock has traded between a high of $126.38 and a low of $28.66.

CORT News

Zacks 2d
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Zacks Investment Research

...

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Zacks Investment Research
Simply Wall St 7d
Is Corcept Therapeutics Undervalued Or Is Its Big Run Already Priced In?

Options activity around Corcept Therapeutics (CORT) has picked up after the November 20, 2026 $47.50 put contract showed unusually high implied volatility, whic...

Is Corcept Therapeutics Undervalued Or Is Its Big Run Already Priced In?

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.